B
Bullisch
Bullisch · 25%AAPG
$58.30
Szenariopreis
$15.060
-0.245 (-1.63%)Zum Schluss
Loading chart…
- Hoch
- 16.070
- Eröffnung
- 15.060
- Volumengewichteter Durchschnittskurs
- 15.32
- Volumen
- 10.26K
- Marktkap.
- —
- Tief
- 14.830
- Umsatz
- 157.17K
- EV/EBITDA, TTM
- -0.46
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
KI-Analyse of Ascentage Pharma Group International (AAPG)
HaltenAscentage Pharma (AAPG) is currently not a strong buy due to its recent performance and mixed analyst ratings. The stock is trading at $14.75, significantly down 44.07% year-to-date and 59.53% over the past year. The RSI is at 42.26, indicating it is near oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is at 10.06, which is relatively low, suggesting the stock may be undervalued. The main risk is the significant revenue decline of 38.9% year-over-year, which raises concerns about the company's growth prospects.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Ascentage Pharma Group International (AAPG) beträgt 10.06, verglichen mit dem 5-Jahres-Durchschnitt von -23.40.
Alphio-AI-Kursszenarien für AAPG
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
9.508-19NewsfilterAscentage Pharma Reports 29% Revenue Growth in H1 2026
5.008-02GlobenewswireAscentage Pharma Appoints New Executives to Strengthen Global Business
- 5.008-02Newsfilter
Ascentage Pharma Appoints New Executives to Strengthen Global Business
8.507-26GlobenewswireDr. Dajun Yang Named No. 3 on The Medicine Maker Power List 2026
- 8.507-26Newsfilter
Dr. Dajun Yang Named No. 3 on The Medicine Maker Power List 2026
AAPG FAQ – beantwortet von Alphio AI
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market. It operates in the Healthcare sector.
Ascentage Pharma (AAPG) is currently not a strong buy due to its recent performance and mixed analyst ratings. The stock is trading at $14.75, significantly down 44.07% year-to-date and 59.53% over the past year. The RSI is at 42.26, indicating it is near oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is at 10.06, which is relatively low, suggesting the stock may be undervalued. The main risk is the significant revenue decline of 38.9% year-over-year, which raises concerns about the company's growth prospects.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.